Oct 29, 2020 / 12:00PM GMT
Operator
Good day, everyone, and welcome to the conference call of Takeda Pharmaceutical Company Limited. (Operator Instructions)
Now we start the conference. Mr. O'Reilly, please go ahead.
Christopher David O'Reilly - Takeda Pharmaceutical Company Limited - Global Head of IR & Global Finance
Hello. Good evening, everyone. Thank you very much for joining this conference call to discuss the fiscal 2020 second quarter financial results of Takeda Pharmaceutical Company. My name is Christopher O'Reilly, Global Head of Investor Relations.
Before starting, I'd like to remind everyone that we will be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today. The factors that could cause our actual results to differ materially are discussed in our most recent Form 20-F and our other SEC filings. Please also refer to the important notice on Page 1 of the earnings presentation.
Now please let me introduce to you
Q2 2021 Takeda Pharmaceutical Co Ltd Earnings Call - Q&A Session Transcript
Oct 29, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers